Literature DB >> 27241893

Serum Bicarbonate and Structural and Functional Cardiac Abnormalities in Chronic Kidney Disease - A Report from the Chronic Renal Insufficiency Cohort Study.

Mirela Dobre1, Jason Roy, Kaixiang Tao, Amanda H Anderson, Nisha Bansal, Jing Chen, Rajat Deo, Paul Drawz, Harold I Feldman, L Lee Hamm, Thomas Hostetter, John W Kusek, Claudia Lora, Akinlolu O Ojo, Kumar Shrama, Mahboob Rahman.   

Abstract

BACKGROUND: Heart failure (HF) is a frequent occurrence in chronic kidney disease (CKD) patients and predicts poor survival. Serum bicarbonate is associated with increased rates of HF in CKD; however, the mechanisms leading to this association are incompletely understood. This study aims to assess whether serum bicarbonate is independently associated with structural and functional cardiac abnormalities in CKD.
METHODS: The association between serum bicarbonate and left ventricular (LV) hypertrophy (LVH), LV mass indexed to height2.7, LV geometry, ejection fraction (EF) and diastolic dysfunction was assessed in 3,483 participants without NYHA class III/IV HF, enrolled in the Chronic Renal Insufficiency Cohort study.
RESULTS: The mean estimated glomerular filtration rate was 42.5 ± 17 ml/min/1.73 m2. The overall prevalence of LVH was 51.2%, with 57.8, 50.9 and 47.7% for bicarbonate categories <22, 22-26 and >26 mmol/l, respectively. Participants with low bicarbonate were more likely to have LVH and abnormal LV geometry (OR 1.32; 95% CI 1.07-1.64, and OR 1.57; 95% CI 1.14-2.16, respectively). However, the association was not statistically significant after adjustment for demographics, traditional cardiovascular risk factors, medications and kidney function (OR 1.07; 95% CI 0.66-1.72, and OR 1.27; 95% CI 0.64-2.51, respectively). No association was found between bicarbonate and systolic or diastolic dysfunction. During follow-up, no significant changes in LV mass or EF were observed in any bicarbonate strata.
CONCLUSIONS: In a large CKD study, serum bicarbonate was associated with LV mass and concentric LVH; however, this association was attenuated after adjustment for clinical factors suggesting that the observed cardiac effects are mediated through yet unknown mechanisms.
© 2016 Published by S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27241893      PMCID: PMC4936954          DOI: 10.1159/000446860

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  46 in total

1.  Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.

Authors:  A Levin; C R Thompson; J Ethier; E J Carlisle; S Tobe; D Mendelssohn; E Burgess; K Jindal; B Barrett; J Singer; O Djurdjev
Journal:  Am J Kidney Dis       Date:  1999-07       Impact factor: 8.860

2.  Stability studies of twenty-four analytes in human plasma and serum.

Authors:  Bobby L Boyanton; Kenneth E Blick
Journal:  Clin Chem       Date:  2002-12       Impact factor: 8.327

Review 3.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography.

Authors:  Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista
Journal:  J Am Soc Echocardiogr       Date:  2009-02       Impact factor: 5.251

4.  Association of echocardiographic abnormalities with mortality in men with non-dialysis-dependent chronic kidney disease.

Authors:  Jason Payne; Smriti Sharma; Dexter De Leon; Jun L Lu; Fregenet Alemu; Rasheed A Balogun; Sandra M Malakauskas; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Nephrol Dial Transplant       Date:  2011-05-25       Impact factor: 5.992

Review 5.  Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment.

Authors:  Jeffrey A Kraut; Ira Kurtz
Journal:  Am J Kidney Dis       Date:  2005-06       Impact factor: 8.860

Review 6.  Left ventricular mass in chronic kidney disease and ESRD.

Authors:  Richard J Glassock; Roberto Pecoits-Filho; Silvio H Barberato
Journal:  Clin J Am Soc Nephrol       Date:  2009-12       Impact factor: 8.237

7.  Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease--a cross-sectional study of predialysis, dialysis and kidney-transplantation patients.

Authors:  Alejandro Recio-Mayoral; Debasish Banerjee; Chris Streather; Juan Carlos Kaski
Journal:  Atherosclerosis       Date:  2011-02-18       Impact factor: 5.162

8.  Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy.

Authors:  M M Sayed-Ahmed; M M Khattab; M Z Gad; A M Osman
Journal:  Pharmacol Toxicol       Date:  2001-09

9.  The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study.

Authors:  M S Lauer; K M Anderson; W B Kannel; D Levy
Journal:  JAMA       Date:  1991-07-10       Impact factor: 56.272

10.  Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.

Authors:  James P Lash; Alan S Go; Lawrence J Appel; Jiang He; Akinlolu Ojo; Mahboob Rahman; Raymond R Townsend; Dawei Xie; Denise Cifelli; Janet Cohan; Jeffrey C Fink; Michael J Fischer; Crystal Gadegbeku; L Lee Hamm; John W Kusek; J Richard Landis; Andrew Narva; Nancy Robinson; Valerie Teal; Harold I Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

View more
  5 in total

1.  Metabolic Acidosis and Cardiovascular Disease Risk in CKD.

Authors:  Matthew K Abramowitz
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-20       Impact factor: 8.237

2.  Serum bicarbonate and cardiovascular events in hypertensive adults: results from the Systolic Blood Pressure Intervention Trial.

Authors:  Mirela Dobre; Nicholas M Pajewski; Srinivasan Beddhu; Michel Chonchol; Thomas H Hostetter; Ping Li; Mahboob Rahman; Karen Servilla; Daniel E Weiner; Jackson T Wright; Kalani L Raphael
Journal:  Nephrol Dial Transplant       Date:  2020-08-01       Impact factor: 5.992

3.  Metabolic Acidosis and Cardiovascular Disease in CKD.

Authors:  David Collister; Thomas W Ferguson; Susan E Funk; Nancy L Reaven; Vandana Mathur; Navdeep Tangri
Journal:  Kidney Med       Date:  2021-06-27

4.  Metabolic acidosis of chronic kidney disease and subclinical cardiovascular disease markers: Friend or foe?

Authors:  Cristina Căpuşă; Gabriel Ştefan; Simona Stancu; Mariana Lipan; Lilach Daniel Tsur; Gabriel Mircescu
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

5.  Veverimer: an advance in base therapy for metabolic acidosis.

Authors:  Clayton Brady; Elie R Chemaly; James W Lohr; Mark D Parker
Journal:  Ann Transl Med       Date:  2020-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.